Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

784
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
784
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

532
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
532
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

1.0K
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
1.0K
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

352
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
352
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

556
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
556
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

1.4K
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.4K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Weight change and long-term cardiovascular outcomes in overweight and obese patients after acute coronary syndromes.

European heart journal open·2026
Same author

Potential impact on cholesterol goal achievement and predicted cardiovascular risk by the addition of ezetimibe and bempedoic acid on top of statins: a simulation from the SANTORINI study.

American journal of preventive cardiology·2026
Same author

Does HDL-C matter when predicting risk of cardiovascular disease in older people with type 2 diabetes?

European journal of preventive cardiology·2026
Same author

Safety of low lipoprotein(a) levels: the FOURIER trial.

European heart journal·2026
Same author

Lipid clinics worldwide: harmonization and guidance on how to optimally organize and fund. European Atherosclerosis Society consensus statement across 55 countries and more than 500 lipid clinics.

Atherosclerosis·2026
Same author

Practical Recommendations for Anticoagulation in Patients With Atrial Fibrillation.

European journal of clinical investigation·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

[Erythema multiforme : target deciphering].

Revue medicale suisse·2026
查看所有相关文章

相关实验视频

Updated: Mar 6, 2026

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.3K

[人工智能将如何改善心血管疾病的预防?]

Andrei Alexandru Mircea1,2, Emmanuel Abbé3, Adèle Mackowiak2

  • 1Centre de médecine générale et santé publique, Unisanté, 1010 Lausanne.

Revue medicale suisse
|March 5, 2026
PubMed
概括
此摘要是机器生成的。

人工智能 (AI) 正在改变心血管预防,使患者能够管理风险因素,并帮助临床医生提高患者护理. 虽然智能手表和大型语言模型是集成的,但人工智能驱动的风险得分需要进一步验证.

更多相关视频

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program
04:24

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program

Published on: April 19, 2019

12.7K
Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

8.1K

相关实验视频

Last Updated: Mar 6, 2026

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.3K
A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program
04:24

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program

Published on: April 19, 2019

12.7K
Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

8.1K

科学领域:

  • 心脏病学 心脏病学
  • 医疗信息学 医疗信息学
  • 人工智能的人工智能

背景情况:

  • 人工智能 (AI) 越来越多地融入日常生活和医疗实践.
  • 人工智能为增强心血管预防策略提供了新的机会.
  • 目前的临床实践开始纳入人工智能工具,如智能手表和大型语言模型.

研究的目的:

  • 探索AI在心血管预防中的双重作用:患者自我管理和临床医生实践增强.
  • 概述人工智能如何促进患者教育和心血管风险因素的管理.
  • 详细介绍AI工具如何改善医疗保健提供者的临床决策和工作流程.

主要方法:

  • 审查目前在心血管健康中的AI应用.
  • 分析面向患者的AI工具,用于风险因素管理和教育.
  • 检查人工智能技术,协助临床医生在心血管实践.
  • 讨论人工智能工具的整合状态,如智能手表和大型语言模型.
  • 考虑机器学习和基于遗传数据的风险评分的验证状态.

主要成果:

  • 人工智能为患者提供了管理心血管风险因素和自我教育的工具.
  • 人工智能通过提高诊断能力和治疗计划来帮助临床医生.
  • 智能手表和大型语言模型目前已融入日常临床实践.
  • 基于机器学习和基因数据的心血管风险得分正在验证中.

结论:

  • 人工智能在心血管预防方面变得越来越重要,为患者和临床医生提供了好处.
  • 智能手表和LLM等AI工具的整合正在进展,而先进的风险预测模型正在开发中.
  • 持续的研究和验证是必要的,以充分实现AI在心血管医学中的潜力.